Besides its physiological role as a neurotransmitter, dopamine (DA) induces apoptosis in the central nervous system. This effect is mediated partly by the DA transporter (DAT) and involves reactive oxygen species (ROS) formation as well as oxidative stress. In the pituitary, the inhibitory control by DA of prolactin release and synthesis and lactotrope cell proliferation is well known, while the pro-apoptotic effect of DA remains unclear. Our aim was to study the pro-apoptotic effect of DA in the GH3 mammosomatotrope cell line and determine the DA mechanism that leads to apoptosis in these cells. Using flow cytometry, Western blot, and confocal microscopy, we showed for the first time that DA induced: (1) loss of mitochondrial potential; (2) relocation of Bax to the mitochondria; (3) cytochrome c release; (4) caspase-3 activation, and (5) nuclear fragmentation, resulting in apoptosis. We observed that DAT was expressed in GH3 cells and participated in the DA effect, as apoptosis was significantly reversed in the presence of DAT inhibitors. Direct measurement showed that DA rapidly increased the formation of intracellular ROS. The antioxidant N-acetyl-L-cysteine (NAC) effectively blocked DA-induced ROS formation and apoptosis. Neither JNK nor p38 were involved in this process, so we suggest that the mitochondrial pore of transition is the likely target of the ROS generated by DA. These data provide the first evidence that DA triggers apoptosis in pituitary cells via a mechanism involving DAT and oxidative stress. These findings may be particularly relevant in understanding lactotrope apoptosis during postnatal life.

Keywords:
Apoptosis, Dopamine transporter, Catecholamine, Lactotrope, Oxidative stress, GH3 cells
1.
Cheng N, Maeda T, Kume T, Kaneko S, Kochiyama H, Akaike A, Goshima Y, Misu Y: Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 1996;743:278–283.
2.
Shinkai T, Zhang L, Mathias SA, Roth GS: Dopamine induces apoptosis in cultured rat striatal neurons; possible mechanism of D2-dopamine receptor neuron loss during aging. J Neurosci Res 1997;47:393–399.
3.
Junn E, Mouradian MM: Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J Neurochem 2001;78:374–383.
4.
Simantov R, Blinder E, Ratovitski T, Tauber M, Gabbay M, Porat S: Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience 1996;74:39–50.
5.
Walkinshaw G, Waters CM: Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson’s disease. J Clin Invest 1995;95:2458–2464.
6.
Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E: Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta 1995;1268:171–177.
7.
Green DR, Evan GI: A matter of life and death. Cancer Cell 2002;1:19–30.
8.
Ricci JE, Munoz-Pinedo C, Fitzgerald P, Bailly-Maitre B, Perkins GA, Yadava N, Scheffler IE, Ellisman MH, Green DR: Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 2004;117:773–786.
9.
De Giorgi F, Lartigue L, Bauer MK, Schubert A, Grimm S, Hanson GT, Remington SJ, Youle RJ, Ichas F: The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 2002;16:607–609.
10.
Precht TA, Phelps RA, Linseman DA, Butts BD, Le SS, Laessig TA, Bouchard RJ, Heidenreich KA: The permeability transition pore triggers Bax translocation to mitochondria during neuronal apoptosis. Cell Death Differ 2005;12:255–265.
11.
Barzilai A, Daily D, Zilkha-Falb R, Ziv I, Offen D, Melamed E, Shirvan A: The molecular mechanisms of dopamine toxicity. Adv Neurol 2003;91:73–82.
12.
Berman SB, Hastings TG: Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. J Neurochem 1999;73:1127–1137.
13.
Lee FJ, Liu F, Pristupa ZB, Niznik HB: Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 2001;15:916–926.
14.
Haggi ES, Torres AI, Maldonado CA, Aoki A: Regression of redundant lactotrophs in rat pituitary gland after cessation of lactation. J Endocrinol 1986;111:367–373.
15.
Ahlbom E, Grandison L, Zhivotovsky B, Ceccatelli S: Termination of lactation induces apoptosis and alters the expression of the Bcl-2 family members in the rat anterior pituitary. Endocrinology 1998;139:2465–2471.
16.
Ben Jonathan N, Hnasko R: Dopamine as a prolactin inhibitor. Endocr Rev 2001;22:724–763.
17.
Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E: Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci USA 2002;99:14530–14535.
18.
Gruszka A, Pawlikowski M, Kunert-Radek J: Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. Neuro Endocrinol Lett 2001;22:343–348.
19.
Yonezawa K, Tamaki N, Kokunai T: Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat. Neurol Med Chir (Tokyo) 1997;37:901–906.
20.
Oyama Y, Hayashi A, Ueha T, Maekawa K: Characterization of 2′,7′-dichlorofluorescin fluorescence in dissociated mammalian brain neurons: estimation on intracellular content of hydrogen peroxide. Brain Res 1994;635:113–117.
21.
Smith AL: Preparation, properties, and conditions for assay of mitochondria: slaughterhouse material, small-scale. Methods Enzymol 1967;10:81–86.
22.
Kim JS, He L, Lemasters JJ: Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003;304:463–470.
23.
Cronin MJ, Faure N, Martial JA, Weiner RI: Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine. Endocrinology 1980;106:718–723.
24.
Johnston JM, Wood DF, Bolaji EA, Johnston DG: The dopamine D2 receptor is expressed in GH3 cells. J Mol Endocrinol 1991;7:131–136.
25.
Missale C, Castelletti L, Boroni F, Memo M, Spano P: Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology 1991;128:13–20.
26.
Yoshinaga N, Murayama T, Nomura Y: Death by a dopaminergic neurotoxin, 1-methyl-4-phenylpyridinium ion (MPP+) and protection by EGF in GH3 cells. Brain Res 1998;794:137–142.
27.
Torres GE, Gainetdinov RR, Caron MG: Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4:13–25.
28.
Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF: Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644–653.
29.
Hastings TG, Lewis DA, Zigmond MJ: Reactive dopamine metabolites and neurotoxicity: implications for Parkinson’s disease. Adv Exp Med Biol 1996;387:97–106.
30.
Luo Y, Umegaki H, Wang X, Abe R, Roth GS: Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 1998;273:3756–3764.
31.
Kluck RM, Esposti MD, Perkins G, Renken C, Kuwana T, Bossy-Wetzel E, Goldberg M, Allen T, Barber MJ, Green DR, Newmeyer DD: The pro-apoptotic proteins, Bid and Bax, cause a limited permeabilization of the mitochondrial outer membrane that is enhanced by cytosol. J Cell Biol 1999;147:809–822.
32.
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997;139:1281–1292.
33.
Falk T, Meyerhof W, Corrette BJ, Schafer J, Bauer CK, Schwarz JR, Richter D: Cloning, functional expression and mRNA distribution of an inwardly rectifying potassium channel protein. FEBS Lett 1995;367:127–131.
34.
Mollard P, Dufy B, Vacher P, Barker JL, Schlegel W: Thyrotropin-releasing hormone activates a [Ca2+]i-dependent K+ current in GH3 pituitary cells via Ins(1,4,5)P3-sensitive and Ins(1,4,5)P3-insensitive mechanisms. Biochem J 1990;268:345–352.
35.
Czarnecki A, Dufy-Barbe L, Huet S, Odessa MF, Bresson-Bepoldin L: Potassium channel expression level is dependent on the proliferation state in the GH3 pituitary cell line. Am J Physiol Cell Physiol 2003;284:C1054–C1064.
36.
Vaur S, Bresson-Bepoldin L, Dufy B, Tuffet S, Dufy-Barbe L: Potassium channel inhibition reduces cell proliferation in the GH3 pituitary cell line. J Cell Physiol 1998;177:402–410.
37.
Bianchi P, Seguelas MH, Parini A, Cambon C: Activation of pro-apoptotic cascade by dopamine in renal epithelial cells is fully dependent on hydrogen peroxide generation by monoamine oxidases. J Am Soc Nephrol 2003;14:855–862.
38.
Crompton M: The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341:233–249.
39.
Kowaltowski AJ, Castilho RF, Vercesi AE: Mitochondrial permeability transition and oxidative stress. FEBS Lett 2001;495:12–15.
40.
Valle VG, Fagian MM, Parentoni LS, Meinicke AR, Vercesi AE: The participation of reactive oxygen species and protein thiols in the mechanism of mitochondrial inner membrane permeabilization by calcium plus prooxidants. Arch Biochem Biophys 1993;307:1–7.
41.
Aoki A, de Gaisan EO, Pasolli HA, Torres AI: Disposal of cell debris from surplus lactotrophs of pituitary gland. Exp Clin Endocrinol Diabetes 1996;104:256–262.
42.
Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV: The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 1990;65:461–474.
43.
Gruszka A, Kunert-Radek J, Pawlikowski M: The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma. Folia Histochem Cytobiol 2004;42:35–39.
44.
Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E: Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. Biol Reprod 2000;62:1486–1494.
45.
An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JA: Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 2003;206:49–62.
46.
Mitsuma T, Rhue H, Hirooka Y, Kayama M, Wago T, Takagi J, Adachi K, Ping J, Ohtake M, Nogimori T, Sakai J: Distribution of dopamine transporter in the rat: an immunohistochemical study. Endocr Regul 1998;32:71–75.
47.
DeMaria JE, Nagy GM, Lerant AA, Fekete MI, Levenson CW, Freeman ME: Dopamine transporters participate in the physiological regulation of prolactin. Endocrinology 2000;141:366–374.
48.
Fernandez-Ruiz JJ, Esquifino AI, Steger RW, Amador AG, Bartke A: Presence of tyrosine-hydroxylase activity in anterior pituitary adenomas and ectopic anterior pituitaries in male rats. Brain Res 1987;421:65–68.
49.
Pisera D, Candolfi M, Navarra S, Ferraris J, Zaldivar V, Jaita G, Castro MG, Seilicovich A: Estrogens sensitize anterior pituitary gland to apoptosis. Am J Physiol Endocrinol Metab 2004;287:E767–E771.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.